Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 11/20 | 0.35 |
| ▸ | CA2 | P00918 | 11/20 | 0.35 |
| ▸ | CA9 | Q16790 | 11/20 | 0.35 |
| ▸ | CA12 | O43570 | 10/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474347 | 1.00 | PAX8 (0.41) | PAX8LMNAPRKCAAKT1PTK2 | |
| SCHEMBL16234425 | 0.84 | LMNA (0.38) | LMNAKMT2ATSHR | |
| SCHEMBL14473900 | 0.84 | LMNA (0.38) | LMNAKMT2ATSHR | |
| SCHEMBL16234426 | 0.81 | LMNA (0.40) | PAX8LMNAKMT2ATSHR | |
| SCHEMBL12778793 | 0.79 | CYP2D6 (0.41) | PAX8LMNAPRKCAAKT1PTK2 | |
| SCHEMBL7464539 | 0.78 | LMNA (0.47) | PAX8LMNAPRKCAAKT1PTK2 | |
| SCHEMBL16234461 | 0.77 | PAX8 (0.36) | PAX8LMNAPRKCAAKT1PTK2 | |
| SCHEMBL16273573 | 0.75 | CYP2D6 (0.36) | PAX8PRKCAAKT1PTK2CA1 | |
| SCHEMBL15171149 | 0.75 | TNF (0.35) | PAX8KMT2A | |
| SCHEMBL14817682 | 0.75 | TNF (0.35) | PAX8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336369-A1 | PROCESS FOR PREPARING HEPARINOIDS AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE US LLC (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336369-A1 | PROCESS FOR PREPARING HEPARINOIDS AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | HPSE, STS, F11 | PAX8 4466/4885LMNA 900/4885PRKCA 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.